BACKGROUND AND PURPOSE: Most large, randomized phase III efficacy trials of therapeutic agents in ischemic stroke have failed to find treatment benefit. We determined whether some phase III studies could have been avoided if preceded by smaller single-arm phase II studies to evaluate the futility of proceeding to phase III. METHODS: To provide examples of the application of phase II methodology, we obtained primary outcome data for the active treatment group of 6 phase III ischemic stroke therapy trials. For each study, we estimated the sample size number required for a multistage single-arm study using parameters specified in the original study. We evaluated outcome data for the first number of subjects in the phase III study treatment arm ordered by enrollment dates. We compared the proportion of favorable outcomes to prespecified stopping criteria derived from a single-arm phase II futility design. If the observed proportion of favorable outcomes was less than the stopping criterion, we declared the treatment not sufficiently effective to warrant further evaluation in phase III. RESULTS: We identified 3 trials as futile in phase II; none of 3 showed treatment efficacy in phase III. In the 3 remaining phase II trials in which we did not show futility, one showed efficacy in phase III. CONCLUSIONS: Single-arm phase II futility studies have been underused in stroke research, but provide a strategy for discarding treatments likely to be ineffective in phase III trials.
RCT Entities:
BACKGROUND AND PURPOSE: Most large, randomized phase III efficacy trials of therapeutic agents in ischemic stroke have failed to find treatment benefit. We determined whether some phase III studies could have been avoided if preceded by smaller single-arm phase II studies to evaluate the futility of proceeding to phase III. METHODS: To provide examples of the application of phase II methodology, we obtained primary outcome data for the active treatment group of 6 phase III ischemic stroke therapy trials. For each study, we estimated the sample size number required for a multistage single-arm study using parameters specified in the original study. We evaluated outcome data for the first number of subjects in the phase III study treatment arm ordered by enrollment dates. We compared the proportion of favorable outcomes to prespecified stopping criteria derived from a single-arm phase II futility design. If the observed proportion of favorable outcomes was less than the stopping criterion, we declared the treatment not sufficiently effective to warrant further evaluation in phase III. RESULTS: We identified 3 trials as futile in phase II; none of 3 showed treatment efficacy in phase III. In the 3 remaining phase II trials in which we did not show futility, one showed efficacy in phase III. CONCLUSIONS: Single-arm phase II futility studies have been underused in stroke research, but provide a strategy for discarding treatments likely to be ineffective in phase III trials.
Authors: Marcus W Koch; Lawrence Korngut; David G Patry; Yahya Agha-Khani; Christopher White; Justyna R Sarna; Michael Yeung; V Wee Yong; Daniel Y C Heng; Gary Cutter; Luanne Metz Journal: Nat Rev Neurol Date: 2015-03-17 Impact factor: 42.937
Authors: Magdy Selim; Lydia D Foster; Claudia S Moy; Guohua Xi; Michael D Hill; Lewis B Morgenstern; Steven M Greenberg; Michael L James; Vineeta Singh; Wayne M Clark; Casey Norton; Yuko Y Palesch; Sharon D Yeatts Journal: Lancet Neurol Date: 2019-03-18 Impact factor: 44.182
Authors: Adnan I Qureshi; Saqib A Chaudhry; Farhan Siddiq; Shahram Majidi; Gustavo J Rodriguez; M Fareed K Suri Journal: J Vasc Interv Neurol Date: 2013-12
Authors: Julius Fridriksson; Chris Rorden; Jordan Elm; Souvik Sen; Mark S George; Leonardo Bonilha Journal: JAMA Neurol Date: 2018-12-01 Impact factor: 18.302
Authors: Charity G Moore; Margaret Schenkman; Wendy M Kohrt; Anthony Delitto; Deborah A Hall; Daniel Corcos Journal: Contemp Clin Trials Date: 2013-06-14 Impact factor: 2.226